Oncostatin M in Ulcerative Colitis Patients

Beni-Suef University

Status

Not yet enrolling

Conditions

Ulcerative Colitis

Treatments

Diagnostic Test: Oncostatin M

Study type

Interventional

Funder types

Other

Identifiers

NCT05974332

Beni-Suefu

Details and patient eligibility

About

Ulcerative colitis (UC) is a refractory disease characterized by symptoms such as diarrhea, bloody stools, and abdominal pain with repeated relapses and remissions.

Full description

Evaluation of UC activity is important, and endoscopic evaluations of mucosal inflammation can facilitate subsequent prognostication. On the basis of these considerations, achievement of mucosal healing is important in inflammatory bowel disease (IBD), and evaluation of IBD using endoscopy is extremely important. However, endoscopic examinations are associated with problems such as physical burden to the patient, cost, and risk of complications.

Thus, to avoid the need for frequent endoscopy, noninvasive biomarkers that accurately reflect the endoscopic activity of UC have emerged, and fecal calprotectin (FC) and the fecal immunochemical occult blood test (FIT) are being widely used in clinical practice.

Enrollment

99 estimated patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

All patients aged >18 years and <80 years, of both gender who diagnosed to have UC and given the consent for participation in the study

Exclusion criteria

1- Any patient with systemic inflammation as Bronchial asthma. 2- History of cancer or tumor. 3- Autoimmune disease such as rheumatoid arthritis and systemic lupus erythematous